Collectionner le produit
Détails du produit
Synonyms
LAG3, CD223, FDC
Source
Human LAG-3, His Tag (LA3-H5222) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Leu 450 (Accession # P18627-1).
Predicted N-terminus: Leu 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, and has a calculated MW of 47.1 kDa. The predicted N-terminus is Leu 23. The reducing (R) protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker in SDS-PAGE due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human LAG-3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human LAG-3, His Tag (Cat. No. LA3-H5222) is more than 95% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human LAG-3, His Tag (Cat. No. LA3-H5222) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human LAG3 Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
Protocol
Immobilized Human LAG-3, His Tag (Cat. No. LA3-H5222) at 1 μg/mL (100 μL/well) can bind Tebotelimab with a linear range of 0.5-16 ng/mL (Routinely tested).
Protocol
Immobilized Human LAG-3, His Tag (Cat. No. LA3-H5222) at 5 μg/mL, add increasing concentrations of Tebotelimab (LAG-3 x PD-1 bispecific antibody) and then add Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 26.00 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
1***12019-11-07
J'aimeI purchased Acro's protein many times for experiments. LAG3 was used mostly, and the titer after immunization can reach more than 100,000. It is a very good product.- 1***62019-10-11 J'aimeThe protein was purchased for my study. It has good purity, which ensured that we obtained high-value antiserum in the animal immunization experiments. We performed multiple batches of immunization. They were stable and had good immune effect.
- 1***22019-09-26 J'aimeI used this protein as an immune antigen in antibody development project. We obtained a pretty high serum titer. We purchased several batches of the protein, and performed multiple experiments. It proved that there was basically no difference among the batches.
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Lymphocyte activation gene 3 protein
- Catégorie：
- Nombre de médicaments répertoriés：
1 Détails
- Nombre de médicaments cliniques：
32 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
